ESSA Pharma Inc (EPIX): MC 90/100 mil cash $174.6M reported at...

Reply Private New

Next 10 Prev Next

Send PM Follow Ignore

Followers	8
Posts	1912
Boards Moderated	0
Alias Born	09/10/2012

Frankestin

Re: None

Wednesday, 10/26/2022 9:18:43 AM

Wednesday, October 26, 2022 9:18:43 AM

MC 90/100 mil
cash $174.6M reported at June 30, 2022
Current cash runway through 2024 funds

3 Posters
Today announced the presentation of updated clinical data from the first two cohorts of the Phase 1/2 study of ESSA's lead candidate EPI-7386 in combination with enzalutamide in patients with metastatic castration-resistant prostate cancer ("mCRPC"). Data will be presented in a poster format at the 2022 Prostate Cancer Foundation ("PCF") Scientific Retreat, taking place October 27-29, 2022 in Carlsbad, CA.

The safety of the combination was favorable with a safety profile consistent with second-generation antiandrogens and no dose limiting toxicities observed.

Two additional posters will be presented at the conference highlighting updated results from the first-in-human Phase 1a dose escalation study of EPI-7386 as a monotherapy in mCRPC patients failing current second-generation antiandrogens and preclinical data on ESSA's first-in-class N-terminal domain androgen receptor protein degrader ("ANITAC"™) program.